Delinaer Wuerkenbieke1, Jing Wang1, Yan Li1, Cailing Ma2. 1. Department of Gynecology, The First Teaching Hospital of Xinjiang Medical University, No 137 Liyushan South Road, Urumqi, 830054, Xinjiang, People's Republic of China. 2. Department of Gynecology, The First Teaching Hospital of Xinjiang Medical University, No 137 Liyushan South Road, Urumqi, 830054, Xinjiang, People's Republic of China. cailingma117@126.com.
Abstract
BACKGROUND: Pertuzumab is a humanized mAb that binds to the extracellular region of HER2/ErbB2 and is approved for treating breast cancer. Although ovarian cancer and breast cancer have comparable levels of HER2/ErbB2 expression, clinical studies of pertuzumab in epithelial ovarian cancer patients have not met the same level of success. OBJECTIVES: To investigate the molecular mechanisms by which pertuzumab exerts its anti-tumor effects in ovarian cancer and the mechanisms by which cancer cells achieve pertuzumab resistance. METHODS: We examined expression of miR-150 in ovarian cancer cells treated with pertuzumab or not. miR-150 knockdown impacts on pertuzumab treatment were analyzed by cell proliferation assay, apoptosis analysis and cell cycle analysis. Cell signal pathway was examined by western blot assay. RESULTS: Pertuzumab induced miRNA-150 expression in SKOV3 and SNU119 cells. Furthermore, suppression of miRNA-150 in both cell lines resulted in decreased drug sensitivity to pertuzumab and cell apoptosis. The blockage of G1/S checkpoint by pertuzumab was rescued as well. miRNA-150 knockdown activated PI3K-Akt pathway and LY294002 reversed the effect of miR-150 knockdown. CONCLUSIONS: miRNA-150 downregulation may contribute to the pertuzumab resistance in ovarian cancer via, at least in part, PI3K-akt pathway.
BACKGROUND:Pertuzumab is a humanized mAb that binds to the extracellular region of HER2/ErbB2 and is approved for treating breast cancer. Although ovarian cancer and breast cancer have comparable levels of HER2/ErbB2 expression, clinical studies of pertuzumab in epithelial ovarian cancerpatients have not met the same level of success. OBJECTIVES: To investigate the molecular mechanisms by which pertuzumab exerts its anti-tumor effects in ovarian cancer and the mechanisms by which cancer cells achieve pertuzumab resistance. METHODS: We examined expression of miR-150 in ovarian cancer cells treated with pertuzumab or not. miR-150 knockdown impacts on pertuzumab treatment were analyzed by cell proliferation assay, apoptosis analysis and cell cycle analysis. Cell signal pathway was examined by western blot assay. RESULTS:Pertuzumab induced miRNA-150 expression in SKOV3 and SNU119 cells. Furthermore, suppression of miRNA-150 in both cell lines resulted in decreased drug sensitivity to pertuzumab and cell apoptosis. The blockage of G1/S checkpoint by pertuzumab was rescued as well. miRNA-150 knockdown activated PI3K-Akt pathway and LY294002 reversed the effect of miR-150 knockdown. CONCLUSIONS:miRNA-150 downregulation may contribute to the pertuzumab resistance in ovarian cancer via, at least in part, PI3K-akt pathway.
Entities:
Keywords:
Drug resistance; Ovarian cancer; Pertuzumab; miR-150
Authors: Heather J Bax; Debra H Josephs; Giulia Pellizzari; James F Spicer; Ana Montes; Sophia N Karagiannis Journal: MAbs Date: 2016-08-05 Impact factor: 5.857
Authors: Debora de Melo Gagliato; Denis Leonardo Fontes Jardim; Mario Sergio Pereira Marchesi; Gabriel N Hortobagyi Journal: Oncotarget Date: 2016-09-27